biopharma dive· 1mo ago
saveASCO ‘26: Bispecifics vs. ADCs, a ‘RAS’ revolution and a step change in prostate cancer
June 2, 2026read original ↗
<p>At the year’s biggest cancer meeting, a high-stakes clash between two popular drug classes erupted, and scientists made headway against a once-insurmountable foe.</p>
The original article is no longer reachable from this URL.
read full article on biopharma dive ↗🔗 mentioned in this article
no entities indexed yet
comments(0)
5-min edit window · permanent after that